Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Dermatology
Gastrointestinal Cancers
Questions discussed in this category
Will you be offering patients urea-based creams or topical diclofenac for hand-foot prophylaxis with capecitabine after the D-TORCH trial results?
D-TORCH compared topical diclofenac to placebo
3 Answers available
What advice do you have for the management of nail toxicity associated with pemigatinib and other FGFR inhibitors?
1 Answer available
Would the diagnosis of skin-only morphea (localized scleroderma) alter treatment recommendations for localized anal cancer?
1 Answer available
16565
15443
8006
Papers discussed in this category
Oncologist, 2020 Oct 28
Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines.
JAMA Dermatol, 2017 Jul 01
Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors.
Related Topics in Dermatology
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Gastrointestinal Cancers
Genitourinary Cancers
Melanoma/Skin Cancer